title: Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies.
authors.affiliation: Department of Surgery, Keio University School of Medicine, Tokyo, Japan. yfuchimo@sc.itc.keio.ac.jp
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Fuchimoto
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Morikawa
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kuroda
authors.forename: Seiichi
authors.initials: S
authors.lastname: Hirobe
authors.forename: Shouichiro
authors.initials: S
authors.lastname: Kamagata
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kumagai
authors.forename: Kentaro
authors.initials: K
authors.lastname: Matsuoka
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Morikawa
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D006390:Hemangioendothelioma / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D059885:Kasabach-Merritt Syndrome / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010976:Platelet Count; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D017211:Treatment Failure; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide